JPMorgan Chase & Co. Boosts Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)

JPMorgan Chase & Co. lifted its position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 498.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 149,045 shares of the company's stock after acquiring an additional 124,133 shares during the period. JPMorgan Chase & Co. owned 0.22% of Perspective Therapeutics worth $475,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Vontobel Holding Ltd. purchased a new position in Perspective Therapeutics during the fourth quarter valued at $51,000. Barclays PLC raised its position in shares of Perspective Therapeutics by 587.9% in the 3rd quarter. Barclays PLC now owns 114,075 shares of the company's stock worth $1,523,000 after purchasing an additional 97,493 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Perspective Therapeutics by 41.3% in the 4th quarter. SG Americas Securities LLC now owns 26,088 shares of the company's stock worth $83,000 after purchasing an additional 7,627 shares during the last quarter. HighTower Advisors LLC boosted its stake in Perspective Therapeutics by 26.1% in the 4th quarter. HighTower Advisors LLC now owns 178,111 shares of the company's stock worth $568,000 after purchasing an additional 36,875 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in Perspective Therapeutics by 3.4% during the 4th quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company's stock valued at $458,000 after purchasing an additional 4,693 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company's stock.

Perspective Therapeutics Stock Performance

NYSE:CATX traded down $0.19 during mid-day trading on Tuesday, hitting $2.24. 708,686 shares of the company traded hands, compared to its average volume of 1,027,960. The stock's fifty day moving average price is $2.27 and its 200-day moving average price is $4.18. Perspective Therapeutics, Inc. has a one year low of $1.60 and a one year high of $19.05.

Insider Activity at Perspective Therapeutics

In other news, CEO Johan M. Spoor bought 22,026 shares of the company's stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.24 per share, with a total value of $49,338.24. Following the acquisition, the chief executive officer now owns 59,383 shares of the company's stock, valued at approximately $133,017.92. This represents a 58.96 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert F. Williamson III purchased 38,145 shares of the firm's stock in a transaction on Monday, March 31st. The shares were acquired at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the acquisition, the director now owns 108,982 shares of the company's stock, valued at approximately $233,221.48. This trade represents a 53.85 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 115,696 shares of company stock worth $256,344. 3.52% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on CATX shares. Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. Cantor Fitzgerald raised Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Truist Financial reduced their target price on Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating for the company in a report on Monday, April 7th. Wedbush reaffirmed an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Wednesday, March 26th. Finally, Scotiabank initiated coverage on Perspective Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price objective for the company. One analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $12.75.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.